Granules India reports 1.6 percent fall in Q4 revenue
Bengaluru: Granules India reported a 1.6% decrease in revenue for the fourth quarter on Wednesday, impacted by lower paracetamol sales and price reductions.
The company's consolidated revenue fell year-on-year to 11.76 billion rupees (nearly $141 million) for the three months to March 31.
Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API as well as the finished dosage - the ready-for-consumption product.
Still, weak sales of the drug and price erosion due to heightened competition hurt its revenue. This is despite analysts expecting Indian API makers, including Granules, to benefit from increasing demand from Europe and the U.S., the industry's biggest markets.
Rivals Glenmark Life Sciences and Laurus Labs posted lower fourth-quarter profits.
Glenmark's revenue was hit by issues stemming from the Red Sea crisis while Laurus was challenged by multiple factors including a decline in selling prices of antiretroviral products.
A 9.5% drop in Granules' raw material expenses, meanwhile, helped its quarterly profit climb 8.4% to 1.30 billion rupees.
API makers use a variety of chemicals in their formulations, including hydrochloric acid and chloroform, accounting for a majority of the drug-makers' input costs.
The easing costs had helped its profit marginally climb in the third quarter as well, before which profit fell for two straight quarters.
Read also: Granules India arm gets USFDA nod for Gout flares drug Colchicine
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd